These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25543014)

  • 21. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
    Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
    Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
    Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
    Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
    Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of killer immunoglobulin-like receptor-ligand interactions in human leukocyte antigen-matched sibling hematopoietic stem cell transplantation.
    Kanga U; Mourya M; Seth T; George J; Sood P; Sharma R; Saxena A; Mehra NK
    Transplant Proc; 2012 May; 44(4):919-21. PubMed ID: 22564585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do human leukocyte antigen E polymorphisms influence graft-versus-leukemia after allogeneic hematopoietic stem cell transplantation?
    Hosseini E; Schwarer AP; Ghasemzadeh M
    Exp Hematol; 2015 Mar; 43(3):149-57. PubMed ID: 25434712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
    Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
    Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The FcgammaRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation.
    van der Straaten HM; Fijnheer R; Nieuwenhuis HK; van de Winkel JG; Verdonck LF
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):206-12. PubMed ID: 15744239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
    Clausen J; Wolf D; Petzer AL; Gunsilius E; Schumacher P; Kircher B; Gastl G; Nachbaur D
    Clin Exp Immunol; 2007 Jun; 148(3):520-8. PubMed ID: 17493020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Role of polymorphic adhesion molecules in the development of graft-versus-leukemia effect after HLA-matched allogeneic stem cell transplantation].
    Shiobara S; Sato H; Furukawa T; Tsukada J; Yasue S; Takeda H; Togawa A; Taira M; Sakai Y; Aizawa Y; Nakao S
    Rinsho Ketsueki; 2004 Jul; 45(7):518-23. PubMed ID: 15359910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.
    Locatelli F; Bauquet A; Palumbo G; Moretta F; Bertaina A
    Immunol Lett; 2013; 155(1-2):21-3. PubMed ID: 24091162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
    Kordelas L; Schwich E; Lindemann M; Heinemann FM; Buttkereit U; Horn PA; Beelen DW; Rebmann V
    Front Immunol; 2019; 10():3027. PubMed ID: 31998310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.
    Savani BN; Mielke S; Adams S; Uribe M; Rezvani K; Yong AS; Zeilah J; Kurlander R; Srinivasan R; Childs R; Hensel N; Barrett AJ
    Leukemia; 2007 Oct; 21(10):2145-52. PubMed ID: 17673900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
    Das-Gupta EP; Russell NH; Shaw BE; Pearce RM; Byrne JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):724-33. PubMed ID: 17531783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene Map of the HLA Region, Graves' Disease and Hashimoto Thyroiditis, and Hematopoietic Stem Cell Transplantation.
    Sasazuki T; Inoko H; Morishima S; Morishima Y
    Adv Immunol; 2016; 129():175-249. PubMed ID: 26791860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center.
    Wang Y; Liu DH; Liu KY; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Sun YQ; Huang XJ
    Cancer; 2013 Mar; 119(5):978-85. PubMed ID: 23097265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients.
    Tsamadou C; Fürst D; Vucinic V; Bunjes D; Neuchel C; Mytilineos D; Gramatzki M; Arnold R; Wagner EM; Einsele H; Müller C; Schrezenmeier H; Mytilineos J
    Haematologica; 2017 Nov; 102(11):1947-1955. PubMed ID: 28883078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.